Omnicell (OMCL)
Market Price (2/16/2026): $36.22 | Market Cap: $1.6 BilSector: Health Care | Industry: Health Care Technology
Omnicell (OMCL)
Market Price (2/16/2026): $36.22Market Cap: $1.6 BilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% | Weak multi-year price returns2Y Excs Rtn is -2.8%, 3Y Excs Rtn is -102% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 97x, P/EPrice/Earnings or Price/(Net Income) is 83x |
| Attractive yieldFCF Yield is 5.6% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.0% | |
| Low stock price volatilityVol 12M is 46% | Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.1% | |
| Megatrend and thematic driversMegatrends include Automation & Robotics, and Digital Health & Telemedicine. Themes include Process / Warehouse Automation, AI in Healthcare Management, Show more. | Key risksOMCL key risks include [1] a dependence on a limited number of suppliers for critical components and technology, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 13% |
| Attractive yieldFCF Yield is 5.6% |
| Low stock price volatilityVol 12M is 46% |
| Megatrend and thematic driversMegatrends include Automation & Robotics, and Digital Health & Telemedicine. Themes include Process / Warehouse Automation, AI in Healthcare Management, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -2.8%, 3Y Excs Rtn is -102% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 97x, P/EPrice/Earnings or Price/(Net Income) is 83x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -3.0% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.1% |
| Key risksOMCL key risks include [1] a dependence on a limited number of suppliers for critical components and technology, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Omnicell (OMCL) stock has gained about 10% since 10/31/2025 because of the following key factors:
1. Strong Third Quarter 2025 Financial Results. Omnicell reported robust financial performance for the third quarter of 2025 on October 30, 2025. The company's earnings per share (EPS) of $0.51 significantly surpassed the forecasted $0.36, representing a 41.67% surprise, and its revenue of $310.63 million exceeded expectations by 5.08%. This strong earnings beat drove a positive market reaction, with the stock surging over 10% in pre-market and morning trading on October 30, 2025, which provided strong momentum as the period began on October 31, 2025.
2. Introduction of New Product Innovations and Strategic Focus. The company's strategic advancements in its product portfolio also contributed to investor confidence. Omnicell announced the Titan XT, a next-generation automated dispensing system, in December 2025, and highlighted continued positive feedback on its cloud-based OmniSphere platform. These innovations are central to Omnicell's vision of autonomous medication management and were viewed as key drivers for future growth and market leadership.
Show more
1. Strong Third Quarter 2025 Financial Results. Omnicell reported robust financial performance for the third quarter of 2025 on October 30, 2025. The company's earnings per share (EPS) of $0.51 significantly surpassed the forecasted $0.36, representing a 41.67% surprise, and its revenue of $310.63 million exceeded expectations by 5.08%. This strong earnings beat drove a positive market reaction, with the stock surging over 10% in pre-market and morning trading on October 30, 2025, which provided strong momentum as the period began on October 31, 2025.
2. Introduction of New Product Innovations and Strategic Focus. The company's strategic advancements in its product portfolio also contributed to investor confidence. Omnicell announced the Titan XT, a next-generation automated dispensing system, in December 2025, and highlighted continued positive feedback on its cloud-based OmniSphere platform. These innovations are central to Omnicell's vision of autonomous medication management and were viewed as key drivers for future growth and market leadership.
Show more
Stock Movement Drivers
Fundamental Drivers
The 8.7% change in OMCL stock from 10/31/2025 to 2/15/2026 was primarily driven by a 22.7% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.57 | 36.50 | 8.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,150 | 1,178 | 2.5% |
| Net Income Margin (%) | 2.0% | 1.7% | -15.8% |
| P/E Multiple | 68.0 | 83.4 | 22.7% |
| Shares Outstanding (Mil) | 47 | 46 | 2.7% |
| Cumulative Contribution | 8.7% |
Market Drivers
10/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| OMCL | 8.7% | |
| Market (SPY) | -0.0% | 28.2% |
| Sector (XLV) | 9.3% | 9.1% |
Fundamental Drivers
The 17.7% change in OMCL stock from 7/31/2025 to 2/15/2026 was primarily driven by a 22.3% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 31.01 | 36.50 | 17.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,136 | 1,178 | 3.7% |
| Net Income Margin (%) | 1.9% | 1.7% | -9.3% |
| P/E Multiple | 68.2 | 83.4 | 22.3% |
| Shares Outstanding (Mil) | 47 | 46 | 2.3% |
| Cumulative Contribution | 17.7% |
Market Drivers
7/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| OMCL | 17.7% | |
| Market (SPY) | 8.2% | 26.8% |
| Sector (XLV) | 21.4% | 13.8% |
Fundamental Drivers
The -18.9% change in OMCL stock from 1/31/2025 to 2/15/2026 was primarily driven by a -27.7% change in the company's P/S Multiple.| (LTM values as of) | 1312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 44.99 | 36.50 | -18.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,064 | 1,178 | 10.7% |
| P/S Multiple | 2.0 | 1.4 | -27.7% |
| Shares Outstanding (Mil) | 46 | 46 | 1.3% |
| Cumulative Contribution | -18.9% |
Market Drivers
1/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| OMCL | -18.9% | |
| Market (SPY) | 14.3% | 38.3% |
| Sector (XLV) | 8.8% | 27.8% |
Fundamental Drivers
The -34.2% change in OMCL stock from 1/31/2023 to 2/15/2026 was primarily driven by a -53.9% change in the company's Net Income Margin (%).| (LTM values as of) | 1312023 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 55.47 | 36.50 | -34.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,309 | 1,178 | -10.0% |
| Net Income Margin (%) | 3.7% | 1.7% | -53.9% |
| P/E Multiple | 51.3 | 83.4 | 62.6% |
| Shares Outstanding (Mil) | 44 | 46 | -2.4% |
| Cumulative Contribution | -34.2% |
Market Drivers
1/31/2023 to 2/15/2026| Return | Correlation | |
|---|---|---|
| OMCL | -34.2% | |
| Market (SPY) | 74.0% | 24.7% |
| Sector (XLV) | 23.7% | 22.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| OMCL Return | 50% | -72% | -25% | 18% | 2% | -20% | -70% |
| Peers Return | 13% | 13% | 11% | 7% | 15% | 2% | 78% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| OMCL Win Rate | 58% | 25% | 50% | 42% | 50% | 50% | |
| Peers Win Rate | 53% | 53% | 58% | 55% | 58% | 70% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| OMCL Max Drawdown | -2% | -74% | -42% | -32% | -45% | -20% | |
| Peers Max Drawdown | -7% | -17% | -13% | -8% | -15% | -3% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BDX, BAX, MCK, CAH, SYK. See OMCL Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
| Event | OMCL | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -84.1% | -25.4% |
| % Gain to Breakeven | 528.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -38.6% | -33.9% |
| % Gain to Breakeven | 62.8% | 51.3% |
| Time to Breakeven | 230 days | 148 days |
| 2018 Correction | ||
| % Loss | -26.4% | -19.8% |
| % Gain to Breakeven | 35.9% | 24.7% |
| Time to Breakeven | 147 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -78.0% | -56.8% |
| % Gain to Breakeven | 353.7% | 131.3% |
| Time to Breakeven | 2,068 days | 1,480 days |
Compare to BDX, BAX, MCK, CAH, SYK
In The Past
Omnicell's stock fell -84.1% during the 2022 Inflation Shock from a high on 11/23/2021. A -84.1% loss requires a 528.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Omnicell (OMCL)
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
AI Analysis | Feedback
Here are two analogies to describe Omnicell:
- Toast for hospital medication management: Just as Toast provides integrated hardware and software systems to streamline operations for restaurants, Omnicell offers comprehensive technology solutions, including automated dispensing cabinets and software, to manage and optimize medication workflows in hospitals.
- Zebra Technologies for hospital pharmacies: Similar to how Zebra Technologies provides hardware and software for tracking assets, managing inventory, and improving operational efficiency across various industries, Omnicell specializes in technology that automates and intelligently manages medication inventory and distribution specifically within hospital pharmacies and care settings.
AI Analysis | Feedback
- Automated Medication Dispensing Systems: Hardware solutions like automated cabinets and carts that securely store and dispense medications within healthcare facilities.
- Medication Inventory & Workflow Management Software: Cloud-based and on-premise software platforms that optimize medication tracking, ordering, and pharmacy operational workflows.
- Point-of-Care Medication Management: Integrated solutions providing secure, efficient access to medications for clinicians directly at the patient's bedside or other care locations.
- Medication Adherence Solutions: Products and services designed to assist patients in managing their medication regimens at home, thereby improving adherence and health outcomes.
- Sterile Compounding Automation: Technology and services that automate and enhance the safety and efficiency of preparing sterile medications in hospital pharmacies.
AI Analysis | Feedback
Omnicell (OMCL) primarily sells its medication management solutions and adherence tools to other companies and healthcare organizations, operating on a business-to-business (B2B) model.
Omnicell's customer base is diverse, and the company does not publicly disclose specific major customer companies by name in its SEC filings. This is because its revenue is derived from a broad range of healthcare providers, and no single customer or small group of customers accounts for a significant portion of its revenue (typically 10% or more) that would necessitate individual disclosure.
Instead, Omnicell serves various types of healthcare organizations, including:
- Hospitals and Health Systems: This category includes acute care hospitals, integrated delivery networks (IDNs), and multi-hospital systems. These organizations utilize Omnicell's automated dispensing systems, medication inventory management, and analytics solutions to enhance medication safety and efficiency within their facilities.
- Retail Pharmacies: Both independent and chain pharmacies are customers, leveraging Omnicell's solutions for central fill, robotic dispensing, and medication synchronization to improve operational efficiency, reduce costs, and support patient adherence programs.
- Long-Term Care Facilities and Other Care Settings: Omnicell provides solutions to skilled nursing facilities, assisted living centers, and other post-acute care providers, helping them manage medications, ensure compliance, and improve patient safety in these environments.
AI Analysis | Feedback
null
AI Analysis | Feedback
Here is the management team of Omnicell (OMCL):Randall Lipps, Chairman, President, Chief Executive Officer, and Founder
Randall Lipps founded Omnicell in 1992, inspired by inefficiencies he observed in medical supply management during his daughter's hospitalization. Under his leadership, Omnicell became a publicly traded company in August 2001 and has grown to offer a comprehensive portfolio of medication management solutions. Prior to founding Omnicell, he was Assistant Vice President of Sales and Operations for a division of American Airlines. He also served as a director for Invuity, Inc. from 2013 to 2018.
Baird Radford, Executive Vice President and Chief Financial Officer
Baird Radford joined Omnicell as Executive Vice President and Chief Financial Officer in August 2025, bringing over 30 years of experience in healthcare and technology finance. He previously served as Chief Financial Officer for Allakos Inc., a biotechnology company. Before that, he was Senior Vice President of Finance for Aimmune Therapeutics Inc., which was acquired by Nestle Health Science in late 2020. Radford also held the CFO position at HeartFlow, Inc., an AI health-tech company, where he managed finance and investor relations and raised significant capital. His career also includes leadership roles at Intuitive Surgical, Inc., eBay, Inc., and PricewaterhouseCoopers.
Nnamdi Njoku, Executive Vice President and Chief Operating Officer
Nnamdi Njoku joined Omnicell in October 2024, bringing over 25 years of experience in leading global operations within the healthcare and medical technology sectors. Before joining Omnicell, he served as President – Sports Medicine, Surgical, Upper Extremities and Restorative Therapies of Zimmer Biomet Holdings, Inc. Prior to Zimmer Biomet, Mr. Njoku spent over 18 years in various executive leadership roles at Medtronic plc, including Senior Vice President and President for the Neuromodulation Operating Unit. His background also includes operational and consulting roles at UnitedHealth Group and Deloitte Consulting.
Perry Genova, Senior Vice President, Chief Technology Officer
Perry A. Genova, PhD, joined Omnicell as Senior Vice President, Chief Technology Officer in March 2025. He is an industry thought leader with an extensive background in innovation, growth, and value delivery. His previous roles include Senior Vice President of Research and Development at EndoQuest Robotics and Titan Medical USA, President and CEO at Centauri Robotic Surgical Systems and Oncoscope, and Vice President at GlaxoSmithKline and Kos Pharmaceuticals. Notably, he built an $800 million division at Kos Pharmaceuticals and holds 58 issued U.S. patents.
Corey Manley, Executive Vice President, Chief Legal and Administrative Officer
Corey Manley joined Omnicell in April 2021 as Executive Vice President, Chief Legal and Administrative Officer. He has over 20 years of experience as a legal and business advisor to global technology and healthcare technology companies. Before Omnicell, he was Chief Legal Officer, Corporate Secretary, and Chief Compliance Officer with a global fintech company. He also served as a Partner in the law firms of Kirkland & Ellis and Duane Morris and began his career as an engineer at Motorola.
AI Analysis | Feedback
The key risks to Omnicell's business include:
- Competitive Market and Economic Pressures: Omnicell operates in a highly competitive healthcare automation market, characterized by continuous innovation from both new and existing players. The company faces economic pressures such as rising drug costs, healthcare consolidation, increasing cost pressures, buyer consolidation, and commoditization, which can negatively impact its pricing power, market share, and overall growth trajectory.
- Regulatory and Cybersecurity Risks: Omnicell is subject to stringent healthcare, privacy, and data protection laws and regulations. Non-compliance with these regulations can lead to significant liabilities. Furthermore, the company faces substantial cybersecurity risks, including data breaches and cyber-attacks on its information technology systems and solutions, which could harm its reputation, operational continuity, and financial performance.
- Dependence on a Limited Number of Suppliers: Omnicell relies on a restricted number of suppliers for specific components, equipment, raw materials, and third-party technologies. This dependence exposes the company to the risk of supply chain disruptions, which could impede its ability to meet customer demands and maintain service levels, particularly during periods of global shortages or price fluctuations.
AI Analysis | Feedback
nullAI Analysis | Feedback
Omnicell (OMCL) operates within several significant addressable markets related to healthcare automation and medication management.
The company itself highlights a total addressable market (TAM) exceeding $90 billion. This estimate, as of May 2022, encompasses the United States, UK&I, Germany, France, Spain, the Kingdom of Saudi Arabia, and Australia/New Zealand, indicating a broad global reach for their solutions.
Omnicell's main products and services include medication management solutions (such as automated dispensing cabinets, pharmacy robotics, software, and adherence tools), IV compounding solutions, and healthcare inventory management.
Here are the addressable market sizes for Omnicell's key product and service categories:
- Medication Management Systems: The global medication management system market was estimated at USD 7.8 billion in 2024 and is projected to reach USD 18.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 8.8%. North America is a dominant region within this market, accounting for over 44.5% share and a revenue of USD 3.5 billion in 2024, with projections to reach USD 15.0 billion by 2032.
- Healthcare Inventory Management: The global healthcare inventory management market size was valued at USD 22.1 billion in 2023 and is projected to reach USD 31.1 billion by 2031, with a CAGR of 5.4% from 2024 to 2031. More specifically, the global healthcare inventory management software market was valued at USD 2.43 billion in 2024 and is expected to grow to USD 5 billion by 2035, exhibiting a CAGR of 6.8% between 2025 and 2035. North America held the largest share of this market in 2023.
- IV Compounding Solutions/Automation: The global IV compounding automation market size reached USD 1.84 billion in 2024 and is expected to expand at a CAGR of 8.7% from 2025 to 2033, reaching USD 3.89 billion by 2033. Another report estimated the global IV compounding devices market to reach USD 2.5 billion by 2025, with a CAGR of 12% through 2033. The Intravenous Solution Compounders Market, which includes automated solutions, is estimated to be valued at USD 2.7 billion globally in 2025 and is projected to reach USD 4.9 billion by 2035, with a CAGR of 6.3%. In the U.S. specifically, the intravenous solution compounders market is estimated at USD 914.4 million in 2025, anticipated to reach USD 1.5 billion by 2035. The overall U.S. intravenous solutions market was estimated at USD 5.03 billion in 2024 and is projected to grow to USD 7.91 billion by 2030, at a CAGR of 7.8% from 2025 to 2030.
These market sizes demonstrate substantial and growing opportunities for Omnicell's offerings within the healthcare technology sector.
AI Analysis | Feedback
Here are the expected drivers of future revenue growth for Omnicell (OMCL) over the next 2-3 years:- Growth in Point-of-Care Connected Devices: Omnicell anticipates continued strong demand for its point-of-care connected devices, including products like XT Amplify and XTExtend. This segment has been a core driver for product revenue and overall performance, with strong customer wins with major health systems and government healthcare facilities.
- Expansion of SaaS and Expert Services: The company is focused on driving growth in its subscription-based SaaS (Software as a Service) and Expert Services. These services contribute to annual recurring revenue, leverage established customer relationships, and expand Omnicell's total addressable market (TAM) by catering to the increasing need for provider digitization and an evolving medication supply chain.
- Advancement of Intelligent Medication Management and Autonomous Pharmacy Vision: Omnicell is strategically transforming into an intelligent medication management technology company. This includes the development and adoption of the OmniSphere cloud-based platform, designed to integrate robotics and smart devices for data-driven medication management, ultimately moving closer to the industry's vision of an Autonomous Pharmacy.
- Market Share Gains and Deep Customer Relationships: Omnicell maintains strong relationships with over half of the top 300 U.S. health systems, providing significant opportunities for expansion within its existing customer base and potential market share gains from competitors.
- Continued Innovation and New Solutions: The company emphasizes ongoing innovation and investment in new products and solutions, such as the MedTrack RFID Line, to deliver outcomes-centric solutions and drive long-term sustainable growth. These efforts are expected to continually improve the customer experience and deliver value.
AI Analysis | Feedback
Share Repurchases
- Omnicell authorized a new $75 million stock repurchase program in May 2025, which was substantially completed in the third quarter of 2025 with approximately $62 million in repurchases.
- The company repurchased approximately $74.92 million of shares in 2025 under an ongoing buyback program.
- Omnicell repurchased approximately $52.2 million of its common stock in 2022 and $53.0 million in 2020.
Share Issuance
- In September 2020, Omnicell priced a $500 million private placement of 0.25% Convertible Senior Notes due 2025, yielding approximately $486.5 million in net proceeds.
- In 2025, the company completed a private offering of $172.5 million in 1.00% Convertible Senior Notes due 2029.
Inbound Investments
No information available.Outbound Investments
- In October 2025, Omnicell acquired ANiGENT, LLC, a software company specializing in drug diversion detection.
- In January 2022, Omnicell acquired pharmacy software solutions provider MarkeTouch Media for $82 million in cash.
- Omnicell also acquired Hub and Spoke Innovations Limited in January 2022, which distributes the Pharmaself24 prescription collection kiosk.
Capital Expenditures
- Omnicell's capital allocation has been focused on its "Autonomous Pharmacy" vision, encompassing investments in robotics, smart devices, intelligent software, and expert services to optimize medication management.
- Investments are aimed at developing new products and solutions, accelerating growth in recurring revenue, and expanding cloud-based offerings.
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 198.34 |
| Mkt Cap | 51.2 |
| Rev LTM | 23,520 |
| Op Inc LTM | 2,931 |
| FCF LTM | 3,457 |
| FCF 3Y Avg | 2,772 |
| CFO LTM | 4,219 |
| CFO 3Y Avg | 3,419 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 10.4% |
| Rev Chg 3Y Avg | 6.8% |
| Rev Chg Q | 10.7% |
| QoQ Delta Rev Chg LTM | 2.6% |
| Op Mgn LTM | 1.5% |
| Op Mgn 3Y Avg | 2.4% |
| QoQ Delta Op Mgn LTM | 0.1% |
| CFO/Rev LTM | 10.3% |
| CFO/Rev 3Y Avg | 13.1% |
| FCF/Rev LTM | 5.4% |
| FCF/Rev 3Y Avg | 8.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 51.2 |
| P/S | 1.2 |
| P/EBIT | 19.9 |
| P/E | 30.0 |
| P/CFO | 11.5 |
| Total Yield | 3.7% |
| Dividend Yield | 0.9% |
| FCF Yield 3Y Avg | 5.0% |
| D/E | 0.1 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -0.5% |
| 3M Rtn | 5.6% |
| 6M Rtn | 5.7% |
| 12M Rtn | -6.0% |
| 3Y Rtn | 9.9% |
| 1M Excs Rtn | 2.1% |
| 3M Excs Rtn | 3.1% |
| 6M Excs Rtn | 0.9% |
| 12M Excs Rtn | -20.0% |
| 3Y Excs Rtn | -58.7% |
Comparison Analyses
Price Behavior
Price Behavior
| Market Price | $36.50 | |
| Market Cap ($ Bil) | 1.7 | |
| First Trading Date | 08/09/2001 | |
| Distance from 52W High | -29.0% | |
| 50 Days | 200 Days | |
| DMA Price | $45.62 | $34.63 |
| DMA Trend | up | up |
| Distance from DMA | -20.0% | 5.4% |
| 3M | 1YR | |
| Volatility | 54.6% | 46.4% |
| Downside Capture | 95.60 | 107.44 |
| Upside Capture | 109.67 | 85.60 |
| Correlation (SPY) | 27.2% | 39.9% |
OMCL Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.65 | 0.76 | 0.95 | 0.83 | 0.91 | 0.83 |
| Up Beta | 3.68 | 1.67 | 1.73 | 1.70 | 0.90 | 0.97 |
| Down Beta | 2.03 | 1.23 | 1.18 | 0.65 | 0.98 | 0.91 |
| Up Capture | 145% | 199% | 193% | 135% | 79% | 30% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 12 | 24 | 34 | 67 | 124 | 360 |
| Down Capture | 14% | -156% | -43% | 0% | 95% | 95% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 8 | 17 | 27 | 57 | 125 | 387 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMCL | |
|---|---|---|---|---|
| OMCL | -7.1% | 46.2% | -0.02 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 27.7% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 39.6% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | -4.7% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | 9.9% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 32.5% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 26.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMCL | |
|---|---|---|---|---|
| OMCL | -21.9% | 49.0% | -0.33 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 28.0% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 33.8% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | 4.9% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | 5.3% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 35.2% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 17.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with OMCL | |
|---|---|---|---|---|
| OMCL | 3.1% | 43.1% | 0.23 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 37.1% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 40.4% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 2.7% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 12.5% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | 36.3% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 13.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/5/2026 | -16.3% | ||
| 10/30/2025 | 13.6% | 20.9% | 22.2% |
| 7/31/2025 | 4.4% | 4.7% | 12.1% |
| 5/6/2025 | -15.8% | -9.9% | 2.6% |
| 2/6/2025 | -11.2% | -8.8% | -16.7% |
| 10/30/2024 | 32.2% | 24.1% | 20.8% |
| 8/1/2024 | 33.0% | 33.7% | 54.9% |
| 5/2/2024 | 7.8% | 10.3% | 19.9% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 12 | 12 | 12 |
| # Negative | 12 | 11 | 11 |
| Median Positive | 4.8% | 4.6% | 10.7% |
| Median Negative | -8.5% | -9.9% | -7.4% |
| Max Positive | 33.0% | 33.7% | 54.9% |
| Max Negative | -34.5% | -36.7% | -33.3% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 02/27/2025 | 10-K |
| 09/30/2024 | 11/08/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/04/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 02/25/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 12172025 | 43.30 | 278 | 12,037 | 4,233,874 | Form |
| 2 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 12052025 | 39.90 | 6,106 | 243,629 | 3,921,452 | Form |
| 3 | Lipps, Randall A | CHAIRMAN, PRESIDENT AND CEO | Direct | Sell | 12032025 | 35.97 | 28,250 | 1,016,093 | 13,906,917 | Form |
| 4 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 11182025 | 34.90 | 3,473 | 121,208 | 3,643,141 | Form |
| 5 | Manley, Corey J | EVP&CHIEF LEGAL/ADMIN OFFICER | Direct | Sell | 9162025 | 33.25 | 3,880 | 129,010 | 3,679,212 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.